3-Bromopyruvate alleviates the development of monocrotalineinduced rat pulmonary arterial hypertension by decreasing aerobic glycolysis,inducing apoptosis,and suppressing inflammation  

作　　者：Jie Liu Wang Wang Lei Wang Xian-Mei Qi Yu-Hui Sha Ting Yang 

机构地区：[1]Department of Immunology,Capital Medical University,Beijing 100069,China [2]Department of Physiology and Pathophysiology,Capital Medical University,Beijing 100069,China [3]Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders,Capital Medical University,Beijing 100069,China [4]Department of Respiratory and Critical Care Medicine,China-Japan Friendship Hospital,Beijing 100029,China

出　　处：《Chinese Medical Journal》2020年第1期49-60,共12页中华医学杂志（英文版）

基　　金：This work was supported by grants from the National Natural Science Foundation of China(No.31600939);the Beijing Natural Science Foundation(No.7174280);the Beijing Talents Training Project(No.2015000020124G111).

摘　　要：Background:Pulmonary arterial hypertension(PH)is a progressive disease with limited therapeutic options,ultimately leading to right heart failure and death.Recent findings indicate the role of the Warburg effect(aerobic glycolysis)in the development of PH.However,the effect of the glycolysis inhibitor 3-bromopyruvate(3-BrPA)on the pathogenesis of PH has not been well investigated.This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism.Methods:PH was induced in adult Sprague-Dawley rats by a single intraperitoneal injection of monocrotaline(MCT).3-BrPA,or phosphate-buffered saline(PBS)was administered via intraperitoneal injection every other day from the first day of MCT-injection to 4 weeks of follow-up,and indices such as right ventricular systolic pressure(RVSP),right ventricular hypertrophy index(RVHI),pulmonary arteriolar remodeling indicated by percent media thickness(%MT),lactate levels and glucose consumption,were evaluated.Pulmonary arteriolar remodeling and right ventricular hypertrophy were observed in hematoxylin-eosin-stained lung sections.Western blotting,immunohistochemistry,and/or immunofluorescence analyses were used to measure the expression of relevant proteins.A cytochrome C release apoptosis assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining were used to measure cell apoptosis.Results:MCT-induced PH showed a significant increase in glucose consumption(0 vs.4 weeks:0.87±0.23 vs.2.94±0.47,P=0.0042)and lactate production(0 vs.4 weeks:4.19±0.34 vs.8.06±0.67,P=0.0004).Treatment with 3-BrPA resulted in a concomitant reduction in glucose consumption(1.10±0.35 vs.3.25±0.47,P=0.0063),lactate production(5.09±0.55 vs.8.06±0.67,P=0.0065),MCT-induced increase in RVSP(39.70±2.94 vs.58.85±2.32,P=0.0004),pulmonary vascular remodeling(%MT,43.45%±1.41%vs.63.66%±1.78%,P<0.0001),and right ventricular hypertrophy(RVHI,38.57%±2.69%vs.62.61%±1.57%,P<0.0001)when compared with those of the PBS-treated group.3-BrPA,a hexokinase 2 in

关 键 词：Pulmonary arterial hypertension MONOCROTALINE 3-Bromopyruvate Aerobic glycolysis 

分 类 号：R563[医药卫生—呼吸系统] R96[医药卫生—内科学]